ALN-AT3SC-003: ATLAS INH: A Phase 3 Study to | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 3

1 participants needed

1 Location

Brief description of study

This study will evaluate the efficacy and safety of fitusiran compared to on-demand treatment with bypassing agents, as determined by the frequency of bleeding episodes in enrolled adult subjects who are who have hemophilia A or B with an inhibitor who are not on prophylaxis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Hemophilia
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 830125

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

ALN-AT3SC-003: ATLAS INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B with Inhibitory Antibodies to Factor VIII or IX

Brief description of study

Eligibility of study

Find a site

Interested in the study